Ontology highlight
ABSTRACT:
SUBMITTER: Kumar SK
PROVIDER: S-EPMC3418771 | biostudies-literature | 2012 May
REPOSITORIES: biostudies-literature
Kumar Shaji K SK Hayman Suzanne R SR Buadi Francis K FK Roy Vivek V Lacy Martha Q MQ Gertz Morie A MA Allred Jacob J Laumann Kristina M KM Bergsagel Leif P LP Dingli David D Mikhael Joseph R JR Reeder Craig B CB Stewart A Keith AK Zeldenrust Steven R SR Greipp Philip R PR Lust John A JA Fonseca Rafael R Russell Stephen J SJ Rajkumar S Vincent SV Dispenzieri Angela A
Blood 20120413 21
Light-chain (AL) amyloidosis remains incurable despite recent therapeutic advances. Given the activity of the lenalidomide-alkylating agent combination in myeloma, we designed this phase 2 trial of lenalidomide, cyclophosphamide, and dexamethasone in AL amyloidosis. Thirty-five patients, including 24 previously untreated, were enrolled. Nearly one-half of the patients had cardiac stage III disease and 28% had ≥ 3 organs involved. The overall hematologic response (≥ partial response [PR]) rate wa ...[more]